Caribou had $345.9M in cash, cash equivalents, and marketable securities as of March 31, compared to $372.4M as of December 31, 2023. “We continue to focus on advancing four clinical-stage programs, including the parallel development of our lead allogeneic CAR-T cell therapy CB-010 in oncology and autoimmune diseases following our recent IND clearance in lupus,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer. “Our clinical execution enables two clinical data readouts this year. At ASCO next month, we look forward to presenting initial dose expansion data for CB-010 in patients with second-line large B cell lymphoma. Additionally, by the end of this year we plan to present initial dose escalation data for CB-011 in relapsed or refractory multiple myeloma.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Caribou Biosciences Advances with FDA Clearance and New Trials
- FDA clears Caribou’s IND application for CB-010 to treat lupus and ERL
- Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
Questions or Comments about the article? Write to editor@tipranks.com